Shandong Lanjin Pharmaceuticals Co.,Ltd   Report issue

For profit Phase 3
Founded: Jinan China (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2010
NCT01570049
First Marketed Drug
2019
rosuvastatin (crestor)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SHANDONG

Active Ingredients

Marketed Drugs (3)

isosorbide (isordil) (2022)

milrinone (primacor) (2023)

rosuvastatin (crestor) (2019)

Drugs in Phase 3 Trials (3)

bendamustine (treanda) (2 trials)

carmustine (bicnu) (2 trials)

chlorambucil (Leukeran) (1 trial)

Drugs in Other Trials (1)

melphalan (alkeran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Oligodendroglioma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4